ArticleScientific reports2026
Multimodal imaging biomarkers associated with recurrence of diabetic macular edema during aflibercept treat-and-extend therapy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This prospective, non-randomized study aimed to identify multimodal imaging biomarkers predictive of treatment response in diabetic macular edema (DME) patients undergoing intravitreal aflibercept therapy using a treat-and-extend (T&E) regimen. Twenty-eight eyes with center-involved DME received five monthly aflibercept injections followed by an 18-month T&E phase. Imaging biomarkers included hyperreflective foci (HRF) and choroidal vascular index (CVI) on OCT, leakage area and microaneurysm count on fluorescein angiography (FA), and intraretinal microvascular abnormalities (IRMA) on OCT angiography (OCTA). During the T&E phase, treatment intervals were shortened in 39.3% of eyes and maximally extended in 60.7%, with complete macular dryness maintained in 22.6%. The completely dry group showed significant reductions in HRF, CVI, leakage area (84.4%), and microaneurysm count (57.7%). Minimal leakage (< 1 mm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.